Development of a Machine Learning Classifier Based on Radiomic Features Extracted From Post-Contrast 3D T1-Weighted MR Images to Distinguish Glioblastoma From Solitary Brain Metastasis.
brain metastasis
diagnostic decision support system
glioblastoma
machine learning
radiomics
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
12
2020
accepted:
17
06
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
To differentiate Glioblastomas (GBM) and Brain Metastases (BM) using a radiomic features-based Machine Learning (ML) classifier trained from post-contrast three-dimensional T1-weighted (post-contrast 3DT1) MR imaging, and compare its performance in medical diagnosis We enrolled 143 patients (71 GBM and 72 BM) in a retrospective bicentric study from January 2010 to May 2019 to train the classifier. Post-contrast 3DT1 MR images were performed on a 3-Tesla MR unit and 100 radiomic features were extracted. Selection and optimization of the Machine Learning (ML) classifier was performed using a nested cross-validation. Sensitivity, specificity, balanced accuracy, and area under the receiver operating characteristic curve (AUC) were calculated as performance metrics. The model final performance was cross-validated, then evaluated on a test set of 37 patients, and compared to human blind reading using a McNemar's test. The ML classifier had a mean [95% confidence interval] sensitivity of 85% [77; 94], a specificity of 87% [78; 97], a balanced accuracy of 86% [80; 92], and an AUC of 92% [87; 97] with cross-validation. Sensitivity, specificity, balanced accuracy and AUC were equal to 75, 86, 80 and 85% on the test set. Sphericity 3D radiomic index highlighted the highest coefficient in the logistic regression model. There were no statistical significant differences observed between the performance of the classifier and the experts' blinded examination. The proposed diagnostic support system based on radiomic features extracted from post-contrast 3DT1 MR images helps in differentiating solitary BM from GBM with high diagnosis performance and generalizability.
Identifiants
pubmed: 34327133
doi: 10.3389/fonc.2021.638262
pmc: PMC8315001
doi:
Types de publication
Journal Article
Langues
eng
Pagination
638262Informations de copyright
Copyright © 2021 de Causans, Carré, Roux, Tauziède-Espariat, Ammari, Dezamis, Dhermain, Reuzé, Deutsch, Oppenheim, Varlet, Pallud, Edjlali and Robert.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Références
JAMA Oncol. 2016 Dec 1;2(12):1636-1642
pubmed: 27541161
World Neurosurg. 2019 Dec;132:e140-e161
pubmed: 31505292
J Neuroradiol. 1983;10(1):51-80
pubmed: 6345726
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Korean J Radiol. 2020 Oct;21(10):1126-1137
pubmed: 32729271
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Int J Comput Assist Radiol Surg. 2013 Sep;8(5):751-61
pubmed: 23334798
Acta Neurochir (Wien). 2010 Nov;152(11):1893-9
pubmed: 20799046
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
J Neurol. 2001 May;248(5):394-8
pubmed: 11437161
Cancer. 1998 Nov 15;83(10):2181-4
pubmed: 9827723
J Magn Reson Imaging. 2019 Aug;50(2):519-528
pubmed: 30635952
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Front Oncol. 2019 Aug 22;9:806
pubmed: 31508366
Methods. 2021 Apr;188:112-121
pubmed: 32522530
Med Phys. 2019 Aug;46(8):3582-3591
pubmed: 31131906
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Oncotarget. 2016 Oct 18;7(42):69051-69059
pubmed: 27655705
Cancer Imaging. 2012 Oct 26;12:423-36
pubmed: 23108208
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):719-729
pubmed: 27742112
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Eur Radiol. 2018 Sep;28(9):3819-3831
pubmed: 29619517
Sci Rep. 2020 Jul 21;10(1):12110
pubmed: 32694637
Radiology. 2014 Feb;270(2):320-5
pubmed: 24471381
J Radiol. 2006 Jun;87(6 Pt 2):822-32
pubmed: 16778750
Sci Rep. 2020 Jul 23;10(1):12340
pubmed: 32704007
Clin Radiol. 2010 Jul;65(7):517-21
pubmed: 20541651
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
J Neuroradiol. 2012 Dec;39(5):301-7
pubmed: 22197404
Acta Radiol. 2010 Apr;51(3):316-25
pubmed: 20092374
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
J Neuroradiol. 2015 Jul;42(4):212-21
pubmed: 24997477
Wiley Interdiscip Rev Data Min Knowl Discov. 2019 Jul-Aug;9(4):e1312
pubmed: 32089788
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1117-1142
pubmed: 30064704
Cancer Lett. 2019 Jun 1;451:128-135
pubmed: 30878526
Neuro Oncol. 2018 May 18;20(6):848-857
pubmed: 29036412
Ann Oncol. 2017 Jun 1;28(6):1191-1206
pubmed: 28168275
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Infus Nurs. 2004 Jul-Aug;27(4):263-9
pubmed: 15273634
AJR Am J Roentgenol. 2000 Jul;175(1):207-19
pubmed: 10882275
PLoS One. 2019 Mar 7;14(3):e0213459
pubmed: 30845221
Cancer Radiother. 2020 Aug;24(5):453-462
pubmed: 32278653
Eur Radiol. 2021 Apr;31(4):2272-2280
pubmed: 32975661
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Sci Rep. 2020 Feb 28;10(1):3711
pubmed: 32111869